GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TriSalus Life Sciences Inc (NAS:TLSI) » Definitions » Cash-to-Debt

TriSalus Life Sciences (TriSalus Life Sciences) Cash-to-Debt : 7.38 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is TriSalus Life Sciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. TriSalus Life Sciences's cash to debt ratio for the quarter that ended in Dec. 2023 was 7.38.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, TriSalus Life Sciences could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for TriSalus Life Sciences's Cash-to-Debt or its related term are showing as below:

TLSI' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.8   Med: 7.38   Max: No Debt
Current: 7.38

During the past 3 years, TriSalus Life Sciences's highest Cash to Debt Ratio was No Debt. The lowest was 4.80. And the median was 7.38.

TLSI's Cash-to-Debt is ranked better than
69.69% of 861 companies
in the Medical Devices & Instruments industry
Industry Median: 1.91 vs TLSI: 7.38

TriSalus Life Sciences Cash-to-Debt Historical Data

The historical data trend for TriSalus Life Sciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

TriSalus Life Sciences Cash-to-Debt Chart

TriSalus Life Sciences Annual Data
Trend Dec21 Dec22 Dec23
Cash-to-Debt
No Debt 4.80 7.38

TriSalus Life Sciences Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash-to-Debt Get a 7-Day Free Trial 4.80 3.61 2.18 12.60 7.38

Competitive Comparison of TriSalus Life Sciences's Cash-to-Debt

For the Medical Devices subindustry, TriSalus Life Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TriSalus Life Sciences's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, TriSalus Life Sciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where TriSalus Life Sciences's Cash-to-Debt falls into.


TriSalus Life Sciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

TriSalus Life Sciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=11.777 / (0.351 + 1.244)
=7.38

TriSalus Life Sciences's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=11.777 / (0.351 + 1.244)
=7.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TriSalus Life Sciences  (NAS:TLSI) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

TriSalus Life Sciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of TriSalus Life Sciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

TriSalus Life Sciences (TriSalus Life Sciences) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TriSalus Life Sciences Inc (NAS:TLSI) » Definitions » Cash-to-Debt
Comparable Companies
INGN HYBT HYPR CLPT ELMD TELA MGRM AXDX APYX NSPR ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
N/A
Address
6272 W. 91st Avenue, Westminster, CO, USA, 80031
Website
https://trisaluslifesci.com
TriSalus Life Sciences Inc is an oncology company integrating standard-of-care treatments and its investigational immunotherapeutic, SD-101, with disruptive Pressure Enabled Drug Delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. TriSalus is a commercial-stage medical device and Phase I clinical-stage pharmaceutical company.
Executives
Jodi Devlin officer: President, Therapeutics C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
James Alecxih officer: President, Device Technology C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Bryan F. Cox officer: Chief Scientific & Manufact. C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Kerry R Hicks director C/O HEALTHGRADES.COM, 44 UNION BLVD SUITE 600, LAKEOOD CO 80228
George Kelly Martin director C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Jennifer Stevens officer: Chief Regulatory Officer C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Richard Marshak officer: Sr.VP, Corp. Dev. & Strategy C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Mary T Szela director, officer: CEO and President 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Anil K. Singhal director C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Sean Murphy director, officer: Chief Financial Officer C/O NOVAN, INC., 4222 EMPEROR BOULEVAND, SUITE 200, DURHAM NC 27703
Arjun Jj Desai director C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Steven C Katz officer: Chief Medical Officer C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Mats Wahlstrom director, 10 percent owner 500 GOLDEN RIDGE ROAD, SUITE 100, GOLDEN CO 80401
Von Eschenbach Andrew C. director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Equity Ab Frankenius 10 percent owner BOX 984, BORAS V7 SE-501 10